Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

BACKGROUND: In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) score ≥ 11. Eligibility to treatment continuation requires a ≥ 50% MIDAS score redu...

Descripción completa

Detalles Bibliográficos
Autores principales: De Icco, Roberto, Vaghi, Gloria, Allena, Marta, Ghiotto, Natascia, Guaschino, Elena, Martinelli, Daniele, Ahmad, Lara, Corrado, Michele, Bighiani, Federico, Tanganelli, Federica, Bottiroli, Sara, Cammarota, Francescantonio, Sances, Grazia, Tassorelli, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482180/
https://www.ncbi.nlm.nih.gov/pubmed/36115947
http://dx.doi.org/10.1186/s10194-022-01480-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482180/
https://www.ncbi.nlm.nih.gov/pubmed/36115947
http://dx.doi.org/10.1186/s10194-022-01480-2

Ejemplares similares